GeoVax Labs, Inc. SEC 10-Q Report

GeoVax Labs, Inc., a biotechnology company specializing in the development of human vaccines and immunotherapies, has released its Form 10-Q report for the first quarter of 2025. The report highlights significant financial improvements and key advancements in its clinical programs, despite facing operational challenges.

Financial Highlights

• Revenue from government contract: $1.64 million, recognized during the three-month period ended March 31, 2025, associated with the ATI-RRPV Contract.
• Loss from operations: $(5.41) million, improved by $0.48 million compared to the same period in 2024, primarily due to increased revenue.
• Net loss: $(5.36) million, improved by $0.49 million compared to the same period in 2024, reflecting increased revenue and interest income.
• Net loss per common share: $(0.45), compared to $(2.47) in the same period in 2024, reflecting a higher number of shares outstanding.

Business Highlights

• GEO-CM04S1 Vaccine Development: GeoVax is advancing its next-generation COVID-19 vaccine, GEO-CM04S1, through multiple Phase 2 clinical trials. These trials are evaluating its efficacy as a primary vaccine for immunocompromised patients, a booster for patients with chronic lymphocytic leukemia, and a robust booster for healthy individuals previously vaccinated with mRNA vaccines.
• Gedeptin® Clinical Progress: The company has completed a Phase 1/2 clinical trial for Gedeptin®, a gene-directed therapy for solid tumors, specifically targeting advanced head and neck cancers. Plans are underway to initiate a Phase 2 trial to assess its efficacy in combination with an immune checkpoint inhibitor.
• GEO-MVA Vaccine Candidate: GeoVax is developing GEO-MVA, a vaccine candidate for Mpox and smallpox. A clinical batch has been produced under cGMP conditions, and clinical evaluation is planned for 2025.
• ATI-RRPV Contract Termination: The company received a notice to cease all work related to the ATI-RRPV Contract for the development of GEO-CM04S1, as BARDA decided to terminate the contract for convenience.
• Research and Development Focus: The company continues to focus on developing vaccines and immunotherapies against infectious diseases and cancers, with significant resources allocated to advancing its vector platform and conducting clinical trials.
• Future Outlook: GeoVax plans to continue advancing its clinical programs and seeks additional funding through public or private equity, government grants, or strategic partnerships to support its operations beyond the third quarter of 2025.

SEC Filing: GeoVax Labs, Inc. [ GOVX ] - 10-Q - May. 01, 2025